Quick Answer
NEUROCRINE BIOSCIENCES INC reported Stockholders Equity of $3.25 billion for fiscal year 2025.
NEUROCRINE BIOSCIENCES INC Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $3.25B | +25.6% |
| 2024 | $2.59B | +16.0% |
| 2023 | $2.23B | +30.7% |
| 2022 | $1.71B | +24.3% |
| 2021 | $1.37B | +22.0% |
| 2020 | $1.13B | +76.8% |
| 2019 | $636.90M | +32.5% |
| 2018 | $480.80M | +29.2% |
| 2017 | $372.20M | +18.2% |
| 2016 | $314.88M | -25.8% |
| 2015 | $424.45M | +103.4% |
| 2014 | $208.70M | +73.3% |
| 2013 | $120.41M | -22.0% |
| 2012 | $154.37M | +156.9% |
| 2011 | $60.08M | +210.6% |
| 2010 | $19.34M | +389.3% |
| 2009 | $3.95M | -89.2% |
| 2008 | $36.77M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.00B | +10.5% | +11.5% |
| June 30, 2025 | $2.69B | +7.4% | +6.3% |
| March 31, 2025 | $2.54B | +6.3% | -2.1% |
| December 31, 2024 | $2.59B | +16.0% | -4.8% |
| September 30, 2024 | $2.72B | +35.8% | +8.4% |
| June 30, 2024 | $2.51B | +35.4% | +5.2% |
| March 31, 2024 | $2.39B | +41.7% | +6.9% |
| December 31, 2023 | $2.23B | +30.7% | +11.5% |
- NEUROCRINE BIOSCIENCES INC showed an increase of +25.6% in Stockholders Equity compared to the prior fiscal year.
- Over the 2008–2025 period, NEUROCRINE BIOSCIENCES INC’s stockholders equity has grown by 8746.2% (from $36.77 million to $3.25 billion).
- The most recent figure is from NEUROCRINE BIOSCIENCES INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: